Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study

doi:10.4254/wjh.v8.i32.1402

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8121)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

411

WORD

332

HTML

2864

Figures (1-5)

209

Tables (1-3)

242

Sum=4058

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

474

Download

1127

Sum=1601

Publishing Process of This Article

Item

Count

Browse

1034

Download

1428

Sum=2462

Nov 18, 2016 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Hepatol. Nov 18, 2016; 8(32): 1402-1413
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1402

Full Size Figure Download Figure

Figure 3 Intensification with tenofovir (A) or telbivudine (B), virologic response and aminotransferase normalisation at week 104, roadmap intent-to-treat population. ALT: Alanine aminotransferase; HBV: Hepatitis B virus.

Citation: Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016; 8(32): 1402-1413
URL: https://www.wjgnet.com/1948-5182/full/v8/i32/1402.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i32.1402